Panobinostat Plus Bortezomib And Dexamethasone In Patients With Relapsed Or Relapsed And Refractory Multiple Myeloma Who Received Prior Bortezomib And Imids: A Predefined Subgroup Analysis Of Panorama 1.

8526 Background: Panobinostat (PAN) is a potent pan-deacetylase inhibitor (pan-DACi) that targets key biological aberrations in multiple myeloma (MM), including epigenetics and protein metabolism. PAN + bortezomib (BTZ) and dexamethasone (Dex; PAN-BTZ-Dex) led to a clinically relevant and statistically significant increase in progression-free survival (PFS) of ≈4 months compared with placebo + BTZ and Dex (Pbo-BTZ-Dex) in patients (pts) with relapsed or relapsed and refractory MM in the PANORAMA 1 phase 3 clinical trial. Methods: The study design was described previously (San-Miguel. Lancet Oncol. 2014;15:1195-206). For this subanalysis, pts who received prior BTZ and IMiDs (lenalidomide or thalidomide) were analyzed for outcomes and safety. Results: A total of 193 pts (25%) received prior BTZ and IMiDs (PAN-BTZ-Dex [n = 94] or Pbo-BTZ-Dex [n = 99]). Median PFS as determined by investigator assessment for the PAN arm was 10.6 mo (95% CI, 7.6-13.8) vs 5.8 mo (95% CI, 4.4-7.1) for the Pbo arm (HR 0.56 [95% ...